CSI Market
Sign In | Register

Heron Therapeutics Inc (HRTX) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access HRTX quarterly Cash Flow →
From Heron Therapeutics Inc through Dec 31 2021, changes in Dec 31 2025's operating cash flow provide insight into underlying business performance trends.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-20.20
Depreciation & amortization2.31
Amortization of Other Assets0.82
Increase (Decrease) in Deferred Revenue0.00
Asset Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-31.05
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation10.34
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt11.34
Debt Securities Available For Sale Realized Gain Loss-
Retirement And Impairment Of Property And Equipment0.41
Increase Decrease In Clinical Liabilities1.40
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable-10.99
Increase (Decrease) in Accounts Payable-2.72
Increase (Decrease) in Other Accrued Liabilities10.60
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.88
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-0.74
Discontinued operations0.00
Net Cash flow from Operating Activities-27.59
Investing Activities
Capital Expenditures-0.32
Sale of Capital Items0.10
Proceeds from Sale and Maturity of Available-for-sale Securities67.01
Payments to Acquire Available-for-sale Securities, Debt-50.79
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities16.01
Financing Activities
Short-term debt Net105.38
Other borrowing transactions-25.00
Long-term debt - borrowings31.86
Long-term debt - repayments-125.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock19.16
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock7.86
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Common Stock And Common Stock Purchase Warrants Sold In Private Placement Offering Net Of Offering Costs-
Proceeds From Convertible Debt Net Of Issuance Costs-
Gross Proceeds From Equity Unit Financing-
Proceeds From Sale Of Common Stock Net-
Proceeds From Sale Of Units Of Common Stock And Warrants Net-
Proceeds From Issuance Of Common Stock Net Of Issuance Costs-
Proceeds From Conversion Of Convertible Notes Payable-
Net Proceeds From Issuance Of Common Stock Under Equity Incentive Plan-
Proceeds From Payments For Stock Issued Under The Equity Incentive Plan0.16
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities14.43
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-27.81
Total Cash Flow2.85
4 historic quarters locked

Sign in to unlock the full Heron Therapeutics Inc cash flow history.

Sign In Create Free Account

About Heron Therapeutics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: February 26, 2026
  • Source: hrtx-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-073515

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License